Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity

Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity

Bone metastasis is the leading cause of prostate cancer (PCa) mortality, frequently marking the progression to castration-resistant PCa. Dysregulation of the androgen receptor pathway is a common feature of castration-resistant PCa, frequently appearing in association with mTOR pathway deregulations...

Full description

Bibliographic Details
Main Authors: Federico La Manna, Marta De Menna, Nikhil Patel, Sofia Karkampouna, Maria De Filippo, Irena Klima, Peter Kloen, Lijkele Beimers, George N. Thalmann, Rob C. M. Pelger, Estela Jacinto, Marianna Kruithof-de Julio
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
bone metastasis
PDX
mTOR
disulfiram
prostate cancer
ALDH
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01012/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01012/full

Similar Items